Skip to main content
SpringerLink
Log in

Mesenchymal Stem Cells as Cellular Immunotherapeutics in Allogeneic Hematopoietic Stem Cell Transplantation

  • Chapter
  • First Online:
Mesenchymal Stem Cells - Basics and Clinical Application II

Part of the book series: Advances in Biochemical Engineering/Biotechnology ((ABE,volume 130))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

APC:

Antigen presenting cells

BM:

Bone marrow

CR:

Complete response

DC:

Dendritic cell

EBMT:

European Group for Blood and Marrow Transplantation

GvHD:

Graft-versus-host disease

GvL:

Graft-versus-leukemia

(allo-)HSCT:

(allogeneic) Hematopoietic stem cell transplantation

HLA(-G):

Human leukocyte antigen(-G)

HSC:

Hematopoietic stem cell

IDO:

Indoleamine-2,3,-dioxygenase

ISCT:

International Society for Cellular Therapy

IFN:

Interferon

IL:

Interleukin

MSC:

Mesenchymal stem cell

OR:

Overall response

PR:

Partial response

PBSC:

Peripheral blood stem cell

PD-L:

Ligand of the programmed death receptor

PGE2 :

Prostaglandin E2

PL:

Platelet lysate

TGF:

Transforming growth factor

Th:

T helper cells

TNF:

Tumor necrosis factor

UCB:

Umbilical cord blood

References

  1. Abdelrazik H, Spaggiari GM, Chiossone L, Moretta L (2011) Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T- and NK-cell proliferation and function. Eur J Immunol 41:3281–3290

    CAS  Google Scholar 

  2. Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815–1822

    CAS  Google Scholar 

  3. Anderson BE, McNiff JM, Jain D, Blazar BR, Shlomchik WD, Shlomchik MJ (2005) Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood 105:2227–2234

    CAS  Google Scholar 

  4. Arora M, Burns LJ, Davies SM, Macmillan ML, Defor TE, Miller WJ, Weisdorf DJ (2003) Chronic graft-versus-host disease: a prospective cohort study. Biol Blood Marrow Transplant 9:38–45

    Google Scholar 

  5. Arora M, Klein JP, Weisdorf DJ, Hassebroek A, Flowers ME, Cutler CS, Urbano-Ispizua A, Antin JH, Bolwell BJ, Boyiadzis M, Cahn JY, Cairo MS, Isola L, Jacobsohn DA, Jagasia M, Klumpp TR, Lee SJ, Petersdorf EW, Santarone S, Gale RP, Schouten HC, Spellman S, Wingard JR, Horowitz MM, Pavletic SZ (2011) Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood 117:6714–6720

    CAS  Google Scholar 

  6. Avanzini MA, Bernardo ME, Cometa AM, Perotti C, Zaffaroni N, Novara F, Visai L, Moretta A, Del Fante C, Villa R, Ball LM, Fibbe WE, Maccario R, Locatelli F (2009) Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors. Haematologica 94:1649–1660

    CAS  Google Scholar 

  7. Baker MB, Altman NH, Podack ER, Levy RB (1996) The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 183:2645–2656

    CAS  Google Scholar 

  8. Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM, Locatelli F, Fibbe WE (2007) Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 110:2764–2767

    CAS  Google Scholar 

  9. Ballen KK, Koreth J, Chen YB, Dey BR, Spitzer TR (2012) Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood 119:1972–1980

    CAS  Google Scholar 

  10. Barker JN, Wagner JE (2003) Umbilical-cord blood transplantation for the treatment of cancer. Nat Rev Cancer 3:526–532

    CAS  Google Scholar 

  11. Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, Seidel L, Vanbellinghen JF, Hafraoui K, Lejeune M, Gothot A, Fillet G, Beguin Y (2010) Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 16:838–847

    Google Scholar 

  12. Behre G, Theurich S, Weber T, Christopeit M (2009) Reply to ‘the correlation between cotransplantation of mesenchymal stem cells and higher recurrence rates in hematologic malignancy patients: outcome of a pilot clinical study’ by Ning et al. Leukemia 23:178; author reply 179–180

    Google Scholar 

  13. Berger M, Figari O, Bruno B, Raiola A, Dominietto A, Fiorone M, Podesta M, Tedone E, Pozzi S, Fagioli F, Madon E, Bacigalupo A (2008) Lymphocyte subsets recovery following allogeneic bone marrow transplantation (BMT): CD4+ cell count and transplant-related mortality. Bone Marrow Transplant 41:55–62

    CAS  Google Scholar 

  14. Bernardo ME, Avanzini MA, Perotti C, Cometa AM, Moretta A, Lenta E, Del Fante C, Novara F, de Silvestri A, Amendola G, Zuffardi O, Maccario R, Locatelli F (2007) Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. J Cell Physiol 211:121–130

    CAS  Google Scholar 

  15. Bianco P, Riminucci M, Gronthos S, Robey PG (2001) Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 19:180–192

    CAS  Google Scholar 

  16. Boxall SA, Jones E (2012) Markers for characterization of bone marrow multipotential stromal cells. Stem Cells Int 2012:975871

    Google Scholar 

  17. Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J (1996) Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 183:657–661

    CAS  Google Scholar 

  18. Cahn JY, Klein JP, Lee SJ, Milpied N, Blaise D, Antin JH, Leblond V, Ifrah N, Jouet JP, Loberiza F, Ringden O, Barrett AJ, Horowitz MM, Socie G (2005) Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 106:1495–1500

    CAS  Google Scholar 

  19. Choi SW, Kitko CL, Braun T, Paczesny S, Yanik G, Mineishi S, Krijanovski O, Jones D, Whitfield J, Cooke K, Hutchinson RJ, Ferrara JL, Levine JE (2008) Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 112:1539–1542

    CAS  Google Scholar 

  20. Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, Smith V, Khouri I, Giralt S, de Lima M, Hsu Y, Ghosh S, Neumann J, Andersson B, Qazilbash M, Hymes S, Kim S, Champlin R, Donato M (2006) Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 107:3074–3080

    CAS  Google Scholar 

  21. Dao MA, Nolta JA (2000) CD34: to select or not to select? That is the question. Leukemia 14:773–776

    CAS  Google Scholar 

  22. Daubener W, Schmidt SK, Heseler K, Spekker KH, MacKenzie CR (2009) Antimicrobial and immunoregulatory effector mechanisms in human endothelial cells. Indoleamine 2,3-dioxygenase versus inducible nitric oxide synthase. Thromb Haemost 102:1110–1116

    Google Scholar 

  23. Dazzi F, Ramasamy R, Glennie S, Jones SP, Roberts I (2006) The role of mesenchymal stem cells in haemopoiesis. Blood Rev 20:161–171

    CAS  Google Scholar 

  24. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315–317

    CAS  Google Scholar 

  25. Dustin ML (2001) Role of adhesion molecules in activation signaling in T lymphocytes. J Clin Immunol 21:258–263

    CAS  Google Scholar 

  26. Fang B, Song Y, Zhao RC, Han Q, Cao Y (2007) Treatment of resistant pure red cell aplasia after major ABO-incompatible bone marrow transplantation with human adipose tissue-derived mesenchymal stem cells. Am J Hematol 82:772–773

    Google Scholar 

  27. Federmann B, Bornhauser M, Meisner C, Kordelas L, Beelen DW, Stuhler G, Stelljes M, Schwerdtfeger R, Christopeit M, Behre G, Faul C, Vogel W, Schumm M, Handgretinger R, Kanz L, Bethge WA (2012) Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study. Haematologica 97(10):1523–1531

    Google Scholar 

  28. Ferrara JL, Levine JE, Reddy P, Holler E (2009) Graft-versus-host disease. Lancet 373:1550–1561

    CAS  Google Scholar 

  29. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11:945–956

    Google Scholar 

  30. Flemming A, Schallmoser K, Strunk D, Stolk M, Volk HD, Seifert M (2011) Immunomodulative efficacy of bone marrow-derived mesenchymal stem cells cultured in human platelet lysate. J Clin Immunol 31:1143–1156

    Google Scholar 

  31. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M, Hurley C, Kollman C, Anasetti C, Noreen H, Begovich A, Hildebrand W, Petersdorf E, Schmeckpeper B, Setterholm M, Trachtenberg E, Williams T, Yunis E, Weisdorf D (2004) Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104:1923–1930

    CAS  Google Scholar 

  32. Fowler DH, Foley J, Whit-Shan Hou J, Odom J, Castro K, Steinberg SM, Gea-Banacloche J, Kasten-Sportes C, Gress RE, Bishop MR (2004) Clinical “cytokine storm” as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor alpha with severe gut graft-versus-host disease. Clin Gastroenterol Hepatol 2:237–245

    Google Scholar 

  33. Francois M, Copland IB, Yuan S, Romieu-Mourez R, Waller EK, Galipeau J (2012) Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-gamma licensing. Cytotherapy 14:147–152

    CAS  Google Scholar 

  34. Fujii N, Takenaka K, Shinagawa K, Ikeda K, Maeda Y, Sunami K, Hiramatsu Y, Matsuo K, Ishimaru F, Niiya K, Yoshino T, Hirabayashi N, Harada M (2001) Hepatic graft-versus-host disease presenting as an acute hepatitis after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 27:1007–1010

    CAS  Google Scholar 

  35. Gieseke F, Bohringer J, Bussolari R, Dominici M, Handgretinger R, Muller I (2010) Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 116:3770–3779

    CAS  Google Scholar 

  36. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18:295–304

    CAS  Google Scholar 

  37. Goker H, Haznedaroglu IC, Chao NJ (2001) Acute graft-vs-host disease: pathobiology and management. Exp Hematol 29:259–277

    CAS  Google Scholar 

  38. Gonzalo-Daganzo R, Regidor C, Martin-Donaire T, Rico MA, Bautista G, Krsnik I, Fores R, Ojeda E, Sanjuan I, Garcia-Marco JA, Navarro B, Gil S, Sanchez R, Panadero N, Gutierrez Y, Garcia-Berciano M, Perez N, Millan I, Cabrera R, Fernandez MN (2009) Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults. Cytotherapy 11:278–288

    CAS  Google Scholar 

  39. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, Szer J, Lipton J, Schwendener A, Gratwohl M, Frauendorfer K, Niederwieser D, Horowitz M, Kodera Y (2010) Hematopoietic stem cell transplantation: a global perspective. JAMA 303:1617–1624

    CAS  Google Scholar 

  40. Graubert TA, DiPersio JF, Russell JH, Ley TJ (1997) Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest 100:904–911

    CAS  Google Scholar 

  41. Handgretinger R, Chen X, Pfeiffer M, Mueller I, Feuchtinger T, Hale GA, Lang P (2007) Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation. Ann N Y Acad Sci 1106:279–289

    CAS  Google Scholar 

  42. Hao L, Sun H, Wang J, Wang T, Wang M, Zou Z (2012) Mesenchymal stromal cells for cell therapy: besides supporting hematopoiesis. Int J Hematol 95:34–46

    Google Scholar 

  43. Hill GR, Ferrara JL (2000) The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95:2754–2759

    CAS  Google Scholar 

  44. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, Deans RJ, Krause DS, Keating A (2005) Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 7:393–395

    CAS  Google Scholar 

  45. Huang GT, Gronthos S, Shi S (2009) Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in regenerative medicine. J Dent Res 88:792–806

    CAS  Google Scholar 

  46. Inagaki J, Nagatoshi Y, Hatano M, Isomura N, Sakiyama M, Okamura J (2008) Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children. Bone Marrow Transplant 41:571–577

    CAS  Google Scholar 

  47. Jacobsohn DA (2008) Acute graft-versus-host disease in children. Bone Marrow Transplant 41:215–221

    CAS  Google Scholar 

  48. Jacobsohn DA, Vogelsang GB (2007) Acute graft versus host disease. Orphanet J Rare Dis 2:35

    Google Scholar 

  49. Jiang Z, Podack E, Levy RB (2001) Major histocompatibility complex-mismatched allogeneic bone marrow transplantation using perforin and/or Fas ligand double-defective CD4(+) donor T cells: involvement of cytotoxic function by donor lymphocytes prior to graft-versus-host disease pathogenesis. Blood 98:390–397

    CAS  Google Scholar 

  50. Johnston LJ, Brown J, Shizuru JA, Stockerl-Goldstein KE, Stuart MJ, Blume KG, Negrin RS, Chao NJ (2005) Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 11:47–55

    CAS  Google Scholar 

  51. Joo SY, Cho KA, Jung YJ, Kim HS, Park SY, Choi YB, Hong KM, Woo SY, Seoh JY, Cho SJ, Ryu KH (2010) Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner. Cytotherapy 12:361–370

    CAS  Google Scholar 

  52. Karlsson H, Samarasinghe S, Ball LM, Sundberg B, Lankester AC, Dazzi F, Uzunel M, Rao K, Veys P, Le Blanc K, Ringden O, Amrolia PJ (2008) Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood 112:532–541

    CAS  Google Scholar 

  53. Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, Monroy R, Uberti J (2009) Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 15:804–811

    CAS  Google Scholar 

  54. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F (2003) Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101:3722–3729

    CAS  Google Scholar 

  55. Kurtzberg J, Prasad V, Grimley MS, Horn B, Carpenter PA, Jacobsohn D, Prockop S (2010) Allogeneic human mesenchymal stem cell therapy (Prochymal®) as a rescue agent for severe treatment resistant GVHD in pediatric patients. Biol Blood Marrow Transplant 16:S169

    Google Scholar 

  56. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR Jr, Moseley AB, Bacigalupo A (2005) Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 11:389–398

    Google Scholar 

  57. Lazarus HM, Rowe JM (1995) New and experimental therapies for treating graft-versus-host disease. Blood Rev 9:117–133

    CAS  Google Scholar 

  58. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371:1579–1586

    Google Scholar 

  59. Le Blanc K, Mougiakakos D (2012) Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 12:383–396

    Google Scholar 

  60. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363:1439–1441

    Google Scholar 

  61. Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, Ljungman P, Lonnies H, Nava S, Ringden O (2007) Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21:1733–1738

    Google Scholar 

  62. Lee SH, Cheuh HW, Yoo KH, Sung KW, Koo HH, Kim DH, Jung CW, Choi SJ, Oh W, Yang YS (2011) Cotransplantation of third party umbilical cord blood mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood. Biol Blood Marrow Transplant 17:S169–S170

    Google Scholar 

  63. Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY, Carabasi MH, Gale RP, Giralt S, Hale GA, Ilhan O, McCarthy PL, Socie G, Verdonck LF, Weisdorf DJ, Horowitz MM (2002) Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 100:406–414

    CAS  Google Scholar 

  64. Li HW, Sykes M (2012) Emerging concepts in haematopoietic cell transplantation. Nat Rev Immunol 12:403–416

    CAS  Google Scholar 

  65. Li JM, Giver CR, Lu Y, Hossain MS, Akhtari M, Waller EK (2009) Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Immunotherapy 1:599–621

    CAS  Google Scholar 

  66. Liem LM, Fibbe WE, van Houwelingen HC, Goulmy E (1999) Serum transforming growth factor-beta1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus-host disease. Transplantation 67:59–65

    CAS  Google Scholar 

  67. Lin MT, Storer B, Martin PJ, Tseng LH, Gooley T, Chen PJ, Hansen JA (2003) Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 349:2201–2210

    CAS  Google Scholar 

  68. Lin W, Oh SK, Choo AB, George AJ (2012) Activated T cells modulate immunosuppression by embryonic-and bone marrow-derived mesenchymal stromal cells through a feedback mechanism. Cytotherapy 14:274–284

    CAS  Google Scholar 

  69. Liu K, Chen Y, Zeng Y, Xu L, Liu D, Chen H, Zhang X, Han W, Wang Y, Zhao T, Wang J, Han Q, Zhao C, Huang X (2011) Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: a randomized, controlled clinical study. Stem Cells Dev 20:1679–1685

    CAS  Google Scholar 

  70. Loiseau P, Busson M, Balere ML, Dormoy A, Bignon JD, Gagne K, Gebuhrer L, Dubois V, Jollet I, Bois M, Perrier P, Masson D, Moine A, Absi L, Reviron D, Lepage V, Tamouza R, Toubert A, Marry E, Chir Z, Jouet JP, Blaise D, Charron D, Raffoux C (2007) HLA association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. Biol Blood Marrow Transplant 13:965–974

    CAS  Google Scholar 

  71. Lopez F, Parker P, Nademanee A, Rodriguez R, Al-Kadhimi Z, Bhatia R, Cohen S, Falk P, Fung H, Kirschbaum M, Krishnan A, Kogut N, Molina A, Nakamura R, O’Donnell M, Popplewell L, Pullarkat V, Rosenthal J, Sahebi F, Smith E, Snyder D, Somlo G, Spielberger R, Stein A, Sweetman R, Zain J, Forman S (2005) Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 11:307–313

    CAS  Google Scholar 

  72. Lucchini G, Introna M, Dander E, Rovelli A, Balduzzi A, Bonanomi S, Salvadè A, Capelli C, Belotti D, Gaipa G, Perseghin P, Vinci P, Lanino E, Chiusolo P, Orofino MG, Marktel S, Golay J, Rambaldi A, Biondi A, D’Amico G, Biagi E (2010) Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant 16:1293–1301

    Google Scholar 

  73. MacKenzie CR, Heseler K, Muller A, Daubener W (2007) Role of indoleamine 2,3-dioxygenase in antimicrobial defence and immuno-regulation: tryptophan depletion versus production of toxic kynurenines. Curr Drug Metab 8:237–244

    CAS  Google Scholar 

  74. Macmillan ML, Blazar BR, DeFor TE, Wagner JE (2009) Transplantation of ex vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I–II clinical trial. Bone Marrow Transplant 43:447–454

    CAS  Google Scholar 

  75. MacMillan ML, DeFor TE, Weisdorf DJ (2010) The best endpoint for acute GVHD treatment trials. Blood 115:5412–5417

    CAS  Google Scholar 

  76. MacMillan ML, DeFor TE, Weisdorf DJ (2012) What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score. Br J Haematol 157:732–741

    Google Scholar 

  77. Maeda Y, Levy RB, Reddy P, Liu C, Clouthier SG, Teshima T, Ferrara JL (2005) Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease. Blood 105:2023–2027

    CAS  Google Scholar 

  78. Majumdar MK, Thiede MA, Haynesworth SE, Bruder SP, Gerson SL (2000) Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res 9:841–848

    CAS  Google Scholar 

  79. Martin PJ (2008) Study design and endpoints in graft-versus-host disease. Best Pract Res Clin Haematol 21:357–372

    Google Scholar 

  80. Martin PJ, Bachier CR, Klingemann HG, McCarthy PL, Szabolcs P, Uberti JP, Schuster MW, Weisdorf D, Chao NJ, Kebriaei P, Shpall EJ, Macmillan ML, Soiffer RJ (2009) Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. Biol Blood Marrow Transplant 15:777–784

    CAS  Google Scholar 

  81. Martin PJ, Uberti JP, Soiffer RJ, Klingemann H, Waller EK, Daly AS, Herrmann RP, Kebriaei P (2010) Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. Biol Blood Marrow Transplant 16:S169–S170

    Google Scholar 

  82. McGuirk JP, Weiss ML (2011) Promising cellular therapeutics for prevention or management of graft-versus-host disease (a review). Placenta 32(Suppl 4):S304–S310

    CAS  Google Scholar 

  83. Meisel R, Brockers S, Heseler K, Degistirici O, Bulle H, Woite C, Stuhlsatz S, Schwippert W, Jager M, Sorg R, Henschler R, Seissler J, Dilloo D, Daubener W (2011) Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia 25:648–654

    CAS  Google Scholar 

  84. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D (2004) Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103:4619–4621

    CAS  Google Scholar 

  85. Meuleman N, Tondreau T, Ahmad I, Kwan J, Crokaert F, Delforge A, Dorval C, Martiat P, Lewalle P, Lagneaux L, Bron D (2009) Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: a pilot study. Stem Cells Dev 18:1247–1252

    Google Scholar 

  86. Muller A, Heseler K, Schmidt SK, Spekker K, Mackenzie CR, Daubener W (2009) The missing link between indoleamine 2,3-dioxygenase mediated antibacterial and immunoregulatory effects. J Cell Mol Med 13:1125–1135

    Google Scholar 

  87. Muller I, Kordowich S, Holzwarth C, Isensee G, Lang P, Neunhoeffer F, Dominici M, Greil J, Handgretinger R (2008) Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis 40:25–32

    Google Scholar 

  88. Nasef A, Zhang YZ, Mazurier C, Bouchet S, Bensidhoum M, Francois S, Gorin NC, Lopez M, Thierry D, Fouillard L, Chapel A (2009) Selected Stro-1-enriched bone marrow stromal cells display a major suppressive effect on lymphocyte proliferation. Int J Lab Hematol 31:9–19

    CAS  Google Scholar 

  89. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE (2006) Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 177:2080–2087

    CAS  Google Scholar 

  90. Newman RE, Yoo D, LeRoux MA, Danilkovitch-Miagkova A (2009) Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug Targets 8:110–123

    CAS  Google Scholar 

  91. Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J, Yu Z, Li B, Xu C, Li Y, Wang J, Hu J, Lou X, Chen H (2008) The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 22:593–599

    CAS  Google Scholar 

  92. Oevermann L, Handgretinger R (2012) New strategies for haploidentical transplantation. Pediatr Res 71:418–426

    CAS  Google Scholar 

  93. Perez-Simon JA, Diez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD, de Leon A, Valcarcel D, Carreras E, del Canizo MC, Lopez-Fidalgo J, Sierra J, San Miguel JF (2005) Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol 130:394–403

    Google Scholar 

  94. Perez-Simon JA, Lopez-Villar O, Andreu EJ, Rifon J, Muntion S, Campelo MD, Sanchez-Guijo FM, Martinez C, Valcarcel D, Canizo CD (2011) Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. Haematologica 96:1072–1076

    Google Scholar 

  95. Petersdorf EW (2007) Risk assessment in haematopoietic stem cell transplantation: histocompatibility. Best Pract Res Clin Haematol 20:155–170

    CAS  Google Scholar 

  96. Petersdorf EW, Malkki M, Gooley TA, Martin PJ, Guo Z (2007) MHC haplotype matching for unrelated hematopoietic cell transplantation. PLoS Med 4:e8

    Google Scholar 

  97. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284:143–147

    CAS  Google Scholar 

  98. Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E, Genrich K, Mehrotra S, Setty S, Smith B, Bartholomew A (2008) IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 38:1745–1755

    CAS  Google Scholar 

  99. Poloni A, Sartini D, Emanuelli M, Trappolini S, Mancini S, Pozzi V, Costantini B, Serrani F, Berardinelli E, Renzi E, Olivieri A, Leoni P (2011) Gene expression profile of cytokines in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with reduced conditioning. Cytokine 53:376–383

    CAS  Google Scholar 

  100. Ponte AL, Marais E, Gallay N, Langonne A, Delorme B, Herault O, Charbord P, Domenech J (2007) The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 25:1737–1745

    CAS  Google Scholar 

  101. Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D, Broadwater G, Monroy R, Kurtzberg J (2011) Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 17:534–541

    CAS  Google Scholar 

  102. Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A (2007) Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 92:881–888

    CAS  Google Scholar 

  103. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825–828

    CAS  Google Scholar 

  104. Rastegar F, Shenaq D, Huang J, Zhang W, Zhang BQ, He BC, Chen L, Zuo GW, Luo Q, Shi Q, Wagner ER, Huang E, Gao Y, Gao JL, Kim SH, Zhou JZ, Bi Y, Su Y, Zhu G, Luo J, Luo X, Qin J, Reid RR, Luu HH, Haydon RC, Deng ZL, He TC (2010) Mesenchymal stem cells: molecular characteristics and clinical applications. World J Stem Cells 2:67–80

    Google Scholar 

  105. Reisner Y, Hagin D, Martelli MF (2011) Haploidentical hematopoietic transplantation: current status and future perspectives. Blood 118:6006–6017

    CAS  Google Scholar 

  106. Remberger M, Ackefors M, Berglund S, Blennow O, Dahllof G, Dlugosz A, Garming-Legert K, Gertow J, Gustafsson B, Hassan M, Hassan Z, Hauzenberger D, Hagglund H, Karlsson H, Klingspor L, Kumlien G, Le Blanc K, Ljungman P, Machaczka M, Malmberg KJ, Marschall HU, Mattsson J, Olsson R, Omazic B, Sairafi D, Schaffer M, Svahn BM, Svenberg P, Swartling L, Szakos A, Uhlin M, Uzunel M, Watz E, Wernerson A, Wikman A, Wikstrom AC, Winiarski J, Ringden O (2011) Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. Biol Blood Marrow Transplant 17:1688–1697

    Google Scholar 

  107. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, Marschall HU, Dlugosz A, Szakos A, Hassan Z, Omazic B, Aschan J, Barkholt L, Le Blanc K (2006) Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81:1390–1397

    Google Scholar 

  108. Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ, Davies SM, Ferrara JL, Socie G (2006) Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 12:138–151

    Google Scholar 

  109. Salem HK, Thiemermann C (2010) Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 28:585–596

    CAS  Google Scholar 

  110. Salmasian H, Rohanizadegan M, Banihosseini S, Rahimi Darabad R, Rabbani-Anari M, Shakiba A, Ferrara JL (2010) Corticosteroid regimens for treatment of acute and chronic graft versus host disease (GvHD) after allogenic stem cell transplantation. Cochrane Database Syst Rev, CD005565(1)

    Google Scholar 

  111. Saresella M, Rainone V, Al-Daghri NM, Clerici M, Trabattoni D (2012) The PD-1/PD-L1 pathway in human pathology. Curr Mol Med 12:259–267

    CAS  Google Scholar 

  112. Sattler C, Steinsdoerfer M, Offers M, Fischer E, Schierl R, Heseler K, Daubener W, Seissler J (2011) Inhibition of T-cell proliferation by murine multipotent mesenchymal stromal cells is mediated by CD39 expression and adenosine generation. Cell Transplant 20:1221–1230

    Google Scholar 

  113. Schmitz N, Eapen M, Horowitz MM, Zhang MJ, Klein JP, Rizzo JD, Loberiza FR, Gratwohl A, Champlin RE (2006) Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 108:4288–4290

    CAS  Google Scholar 

  114. Schonberger S, Meisel R, Adams O, Pufal Y, Laws HJ, Enczmann J, Dilloo D (2010) Prospective, comprehensive, and effective viral monitoring in children undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 16:1428–1435

    CAS  Google Scholar 

  115. Schonberger S, Niehues T, Meisel R, Bernbeck B, Laws HJ, Kogler G, Enzmann J, Wernet P, Gobel U, Dilloo D (2004) Transplantation of haematopoietic stem cells derived from cord blood, bone marrow or peripheral blood: a single centre matched-pair analysis in a heterogeneous risk population. Klinische Padiatrie 216:356–363

    CAS  Google Scholar 

  116. Schultz KR, Miklos DB, Fowler D, Cooke K, Shizuru J, Zorn E, Holler E, Ferrara J, Shulman H, Lee SJ, Martin P, Filipovich AH, Flowers ME, Weisdorf D, Couriel D, Lachenbruch PA, Mittleman B, Vogelsang GB, Pavletic SZ (2006) Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant 12:126–137

    Google Scholar 

  117. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, Shlomchik MJ, Emerson SG (1999) Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285:412–415

    CAS  Google Scholar 

  118. Sioud M (2011) New insights into mesenchymal stromal cell-mediated T-cell suppression through galectins. Scand J Immunol 73:79–84

    CAS  Google Scholar 

  119. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L (2008) Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111:1327–1333

    CAS  Google Scholar 

  120. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L (2006) Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107:1484–1490

    CAS  Google Scholar 

  121. Sudres M, Norol F, Trenado A, Gregoire S, Charlotte F, Levacher B, Lataillade JJ, Bourin P, Holy X, Vernant JP, Klatzmann D, Cohen JL (2006) Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 176:7761–7767

    CAS  Google Scholar 

  122. Sugiyama T, Nagasawa T (2012) Bone marrow niches for hematopoietic stem cells and immune cells. Inflamm Allergy Drug Targets 11:201–206

    CAS  Google Scholar 

  123. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ (2009) Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. Bone Marrow Transplant 44:453–455

    CAS  Google Scholar 

  124. Tu Z, Li Q, Bu H, Lin F (2010) Mesenchymal stem cells inhibit complement activation by secreting factor H. Stem Cells Dev 19:1803–1809

    CAS  Google Scholar 

  125. van den Brink MR, Burakoff SJ (2002) Cytolytic pathways in haematopoietic stem-cell transplantation. Nat Rev Immunol 2:273–281

    Google Scholar 

  126. von Bonin M, Stolzel F, Goedecke A, Richter K, Wuschek N, Holig K, Platzbecker U, Illmer T, Schaich M, Schetelig J, Kiani A, Ordemann R, Ehninger G, Schmitz M, Bornhauser M (2009) Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 43:245–251

    Google Scholar 

  127. Wagner JE, Gluckman E (2010) Umbilical cord blood transplantation: the first 20 years. Semin Hematol 47:3–12

    Google Scholar 

  128. Waldman E, Lu SX, Hubbard VM, Kochman AA, Eng JM, Terwey TH, Muriglan SJ, Kim TD, Heller G, Murphy GF, Liu C, Alpdogan O, van den Brink MR (2006) Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood 107:1703–1711

    CAS  Google Scholar 

  129. Wang H, Yan H, Wang Z, Zhu L, Liu J, Guo Z (2012) Cotransplantation of allogeneic mesenchymal and hematopoietic stem cells in children with aplastic anemia. Pediatrics 129:e1612–e1615

    Google Scholar 

  130. Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N, Kersey J, Filipovich A (1990) Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 75:1024–1030

    CAS  Google Scholar 

  131. Weisdorf D, Zhang MJ, Arora M, Horowitz MM, Rizzo JD, Eapen M (2012) Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol Blood Marrow Transplant 11:1727–1733

    Google Scholar 

  132. Welniak LA, Blazar BR, Murphy WJ (2007) Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 25:139–170

    CAS  Google Scholar 

  133. Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS, Wu SJ, Luo CW, Guo R, Ling W, Deng CX, Liao PJ, Xiang AP (2010) Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 45:1732–1740

    CAS  Google Scholar 

  134. Wolf D, von Lilienfeld-Toal M, Wolf AM, Schleuning M, von Bergwelt-Baildon M, Held SA, Brossart P (2012) Novel treatment concepts for graft-versus-host disease. Blood 119:16–25

    CAS  Google Scholar 

  135. Yagi H, Soto-Gutierrez A, Parekkadan B, Kitagawa Y, Tompkins RG, Kobayashi N, Yarmush ML (2010) Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant 19:667–679

    Google Scholar 

  136. Yaniv I, Stein J (2008) Reduced-intensity conditioning in children: a reappraisal in 2008. Bone Marrow Transplant 41(Suppl 2):S18–S22

    Google Scholar 

  137. Zhang H, Chen J, Que W (2012) Allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials. Leuk Res 36:431–437

    Google Scholar 

  138. Zhang X, Li JY, Cao K, Lu H, Hong M, Qian S, Wu H, Liu P, Xu W (2010) Cotransplantation of HLA-identical mesenchymal stem cells and hematopoietic stem cells in Chinese patients with hematologic diseases. Int J Lab Hematol 32:256–264

    CAS  Google Scholar 

  139. Zhang YN, Lie PC, Wei X (2009) Differentiation of mesenchymal stromal cells derived from umbilical cord Wharton’s jelly into hepatocyte-like cells. Cytotherapy 11:548–558

    CAS  Google Scholar 

  140. Zhou H, Guo M, Bian C, Sun Z, Yang Z, Zeng Y, Ai H, Zhao RC (2010) Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Biol Blood Marrow Transplant 16:403–412

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Hematology and Oncology, Center for Pediatrics, University Hospital, Friedrich-Wilhelm University, Bonn, Germany

    Claudia Papewalis, Daniela Topolar, Barbara Götz, Stefan Schönberger & Dagmar Dilloo

Authors
  1. Claudia Papewalis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniela Topolar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Barbara Götz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stefan Schönberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dagmar Dilloo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dagmar Dilloo .

Editor information

Editors and Affiliations

  1. Abt. für Plastische und Handchirurgie, Medizinische Hochschule Hannover, Hannover, Germany

    Birgit Weyand

  2. Integrated Department of Oncology, Haematology and Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy

    Massimo Dominici

  3. Medizinische Hochschule Hannover, AG Biochemie und Tumorbiologie, Klinik für Frauenheilkunde und Geburtshilfe, Hannover, Germany

    Ralf Hass

  4. Medizinische Hochschule Hannover, Klinik für Immunologie und Rheumatologie, Hannover, Niedersachsen, Germany

    Roland Jacobs

  5. Department für Biotechnologie, Universität für Bodenkultur, Wien, Austria

    Cornelia Kasper

Rights and permissions

Reprints and permissions

Copyright information

© 2013 2013

About this chapter

Cite this chapter

Papewalis, C., Topolar, D., Götz, B., Schönberger, S., Dilloo, D. (2013). Mesenchymal Stem Cells as Cellular Immunotherapeutics in Allogeneic Hematopoietic Stem Cell Transplantation. In: Weyand, B., Dominici, M., Hass, R., Jacobs, R., Kasper, C. (eds) Mesenchymal Stem Cells - Basics and Clinical Application II. Advances in Biochemical Engineering/Biotechnology, vol 130. Springer, Berlin, Heidelberg. https://doi.org/10.1007/10_2012_158

Download citation

Publish with us

Policies and ethics

Search

Navigation